Skip to main content
Fig. 5 | Breast Cancer Research

Fig. 5

From: Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancer

Fig. 5

Effect of vistusertib alone or in combination with fulvestrant on tumour progression in HBCx22 OvaR PDX models. a Long-term study assessing changes in tumour volume over 93 days of treatment in HBCx22OvaR. HBCx22 OvaR is an ER+ model that shows partial resistance to fulvestrant. Mice were treated with vehicle control, fulvestrant, vistusertib or the combination. Data represents mean relative tumour volume ± SEM. b Effect of vistusertib alone or in combination with fulvestrant on tumour growth of individual mice over a period of 93 days. Treatments were withdrawn and tumour growth reassessed for a further 40 days to establish the efficacy of the drugs in delaying tumour progression. c Immunohistochemical analysis of several markers following treatment for a period of 4 days with either vehicle, vistusertib (Vist), fulvestrant (Fulv) or the combination of both (Vist + Fulv). Tumours were harvested 4 h after the last treatment. Statistical analysis was performed using ANOVA with Dunnett’s multiple comparisons test. #Tendency to difference between groups by t test

Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us